These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18715200)

  • 1. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
    Davies MJ; Derezinski T; Pedersen CB; Clauson P
    Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P
    Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
    Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
    Garber AJ; Clauson P; Pedersen CB; Kølendorf K
    J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
    Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
    Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.
    Pieber TR; Draeger E; Kristensen A; Grill V
    Diabet Med; 2005 Jul; 22(7):850-7. PubMed ID: 15975098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
    Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
    Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
    Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K
    Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC; Bogoev M; Larsen J; Philotheou A
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
    Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.